Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Axillary dissection
Axillary staging
Breast cancer
Breast surgery
Sentinel lymph node procedure
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
07
06
2023
accepted:
18
09
2023
medline:
7
12
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
ppublish
Résumé
Tailored axillary surgery (TAS) is a novel surgical concept for clinical node-positive breast cancer. It consists of the removal of the sentinel lymph nodes (LNs), as well as palpably suspicious nodes. The TAS technique can be utilized in both the upfront and neoadjuvant chemotherapy (NACT) setting. This study assessed whether/how imaging-guided localization (IGL) influenced TAS. This was a prospective observational cohort study preplanned in the randomized phase-III OPBC-03/TAXIS trial. IGL was performed at the surgeon's discretion for targeted removal of LNs during TAS. Immediate back-up axillary lymph node dissection (ALND) followed TAS according to TAXIS randomization. Five-hundred patients were included from 44 breast centers in six countries, 151 (30.2%) of whom underwent NACT. IGL was performed in 84.4% of all patients, with significant variation by country (77.6-100%, p < 0.001). No difference in the median number of removed (5 vs. 4, p = 0.3) and positive (2 vs. 2, p = 0.6) LNs by use of IGL was noted. The number of LNs removed during TAS with IGL remained stable over time (p = 0.8), but decreased significantly without IGL, from six (IQR 4-6) in 2019 to four (IQR 3-4) in 2022 (p = 0.015). An ALND was performed in 249 patients, removing another 12 (IQR 9-17) LNs, in which a median number of 1 (IQR 0-4) was positive. There was no significant difference in residual nodal disease after TAS with or without IGL (68.0% vs. 57.6%, p = 0.2). IGL did not significantly change either the performance of TAS or the volume of residual nodal tumor burden. ClinicalTrials.gov Identifier: NCT03513614.
Sections du résumé
BACKGROUND
BACKGROUND
Tailored axillary surgery (TAS) is a novel surgical concept for clinical node-positive breast cancer. It consists of the removal of the sentinel lymph nodes (LNs), as well as palpably suspicious nodes. The TAS technique can be utilized in both the upfront and neoadjuvant chemotherapy (NACT) setting. This study assessed whether/how imaging-guided localization (IGL) influenced TAS.
PATIENTS AND METHODS
METHODS
This was a prospective observational cohort study preplanned in the randomized phase-III OPBC-03/TAXIS trial. IGL was performed at the surgeon's discretion for targeted removal of LNs during TAS. Immediate back-up axillary lymph node dissection (ALND) followed TAS according to TAXIS randomization.
RESULTS
RESULTS
Five-hundred patients were included from 44 breast centers in six countries, 151 (30.2%) of whom underwent NACT. IGL was performed in 84.4% of all patients, with significant variation by country (77.6-100%, p < 0.001). No difference in the median number of removed (5 vs. 4, p = 0.3) and positive (2 vs. 2, p = 0.6) LNs by use of IGL was noted. The number of LNs removed during TAS with IGL remained stable over time (p = 0.8), but decreased significantly without IGL, from six (IQR 4-6) in 2019 to four (IQR 3-4) in 2022 (p = 0.015). An ALND was performed in 249 patients, removing another 12 (IQR 9-17) LNs, in which a median number of 1 (IQR 0-4) was positive. There was no significant difference in residual nodal disease after TAS with or without IGL (68.0% vs. 57.6%, p = 0.2).
CONCLUSIONS
CONCLUSIONS
IGL did not significantly change either the performance of TAS or the volume of residual nodal tumor burden.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier: NCT03513614.
Identifiants
pubmed: 37903951
doi: 10.1245/s10434-023-14404-4
pii: 10.1245/s10434-023-14404-4
pmc: PMC10695869
doi:
Banques de données
ClinicalTrials.gov
['NCT03513614']
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase III
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
344-355Informations de copyright
© 2023. The Author(s).
Références
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
J Clin Oncol. 2015 Jan 20;33(3):258-64
pubmed: 25452445
J Clin Oncol. 2016 Apr 1;34(10):1072-8
pubmed: 26811528
Br J Surg. 2021 Apr 5;108(3):302-307
pubmed: 33793745
Ann Surg Oncol. 2021 Oct;28(11):6060-6068
pubmed: 33876360
Lancet Oncol. 2013 Jun;14(7):609-18
pubmed: 23683750
N Engl J Med. 2003 Aug 7;349(6):546-53
pubmed: 12904519
Breast. 2023 Jun;69:281-289
pubmed: 36922305
Lancet Oncol. 2010 Oct;11(10):927-33
pubmed: 20863759
Eur J Surg Oncol. 2023 Mar;49(3):589-596
pubmed: 36470801
JAMA. 2013 Oct 9;310(14):1455-61
pubmed: 24101169
Ann Surg Oncol. 2018 Jun;25(6):1512-1520
pubmed: 29511992
Ann Surg Oncol. 2021 May;28(5):2609-2618
pubmed: 33084993
JAMA Surg. 2023 Aug 1;158(8):807-815
pubmed: 37285140
N Engl J Med. 2021 Dec 16;385(25):2336-2347
pubmed: 34914339
Lancet Oncol. 2007 Oct;8(10):881-8
pubmed: 17851130
Ann Oncol. 2021 Oct;32(10):1216-1235
pubmed: 34242744
Ann Surg. 2022 Nov 1;276(5):e553-e562
pubmed: 33156057
Ann Surg Oncol. 2021 Feb;28(2):930-940
pubmed: 32712895
Lancet Oncol. 2018 Oct;19(10):1385-1393
pubmed: 30196031
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Trials. 2018 Dec 4;19(1):667
pubmed: 30514362
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722
pubmed: 35714673
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Cancers (Basel). 2021 Mar 29;13(7):
pubmed: 33805367
Breast. 2021 Dec;60:98-110
pubmed: 34555676
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810544
Breast Cancer Res Treat. 2022 May;193(1):37-48
pubmed: 35239072
Clin Breast Cancer. 2017 Aug;17(5):399-402
pubmed: 28487053
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663
BMJ. 2015 May 08;350:h2147
pubmed: 25956159